RNA - Avidity Biosciences  - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

RNA is currently covered by 11 analysts with an average price target of $69.64. This is a potential upside of $33.4 (92.16%) from yesterday's end of day stock price of $36.24.

Avidity Biosciences 's activity chart (see below) currently has 32 price targets and 67 ratings on display. The stock rating distribution of RNA is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 42.8% with an average time for these price targets to be met of 295.42 days.

Highest price target for RNA is $96, Lowest price target is $53, average price target is $61.82.

Most recent stock forecast was given by ANDREW FEIN from HC WAINWRIGHT on 12-May-2025. First documented stock forecast 07-Jul-2020.

Currently out of the existing stock ratings of RNA, 42 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$68

$31.76 (87.64%)

$72

27 days ago
(12-May-2025)

0/5 (0%)

$38.67 (131.84%)

Buy

$65

$28.76 (79.36%)

$65

30 days ago
(09-May-2025)

8/13 (61.54%)

$37.13 (133.23%)

299

Buy

$60

$23.76 (65.56%)

$60

1 months 30 days ago
(09-Apr-2025)

11/16 (68.75%)

$35.2 (141.94%)

246

Buy

$70

$33.76 (93.16%)

$48

2 months 26 days ago
(13-Mar-2025)

2/4 (50%)

$37.87 (117.86%)

44

Buy

$67

$30.76 (84.88%)

$67

4 months 18 days ago
(21-Jan-2025)

0/2 (0%)

$36.16 (117.25%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RNA (Avidity Biosciences ) average time for price targets to be met?

On average it took 295.42 days on average for the stock forecasts to be realized with a an average price target met ratio 42.8

Which analyst has the current highest performing score on RNA (Avidity Biosciences ) with a proven track record?

JOSEPH STRINGER

Which analyst has the most public recommendations on RNA (Avidity Biosciences )?

Joseph Stringer works at NEEDHAM and has 3 price targets and 5 ratings on RNA

Which analyst is the currently most bullish on RNA (Avidity Biosciences )?

Eric Schmidt with highest potential upside - $59.76

Which analyst is the currently most reserved on RNA (Avidity Biosciences )?

Joseph Schwartz with lowest potential downside - -$18.24

Avidity Biosciences  in the News

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for DMD44, DM1 and FSHD Executing...

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan SAN DIEGO, April 8, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?